A Comparative Clinical Study to Evaluate Efficacy and Safety of Immusante as in the Prevention and Treatment of Chemotherapy Induced Neutropenia

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Both male and female patients aged more than 18 years
•Cancer patients except for blood cancer, receiving chemotherapy and or radiotherapy.
•Performance status Eastern Cooperative oncology Group (ECOG) <= 2
•Patient with a neutrophil count > 500 cell/cc
•Patients who were known to had Neutrophilia in the first cycle of chemotherapy of planned chemotherapy of four cycles.
•Patients who are planned with at least four more cycles of chemotherapy.
•Able to comply with the protocol and willing to sign the informed consent form.

•Patients with active uncontrolled infection
•Inadequate renal or hepatic function tests.
•Any evidence or history of hypersensitivity to herbal medicines.
•Recurrent/refractory/metastatic carcinomas
•Severe, life threatening complications associated with carcinoma
•Severe febrile neutropenia with neutrophil count of 500 cells/cc or below
•Not recovered from acute toxicities of the prior therapies.
•Not willing to sign the informed consent or abide by the study procedure.
•Pregnant or lactating women or women in the reproductive age group not willing to use an effective contraceptive measures.

发起方